Beta-hydroxybutyrate testing is used as the mainstay in the diagnosis of diabetic ketoacidosis and other ketonic states. Strides in assays have led to the testing modalities being remarkable precise and of high analytical performance. Routine urine laboratory analysis is used to confirm the condition. The testing is used in diagnosis and monitoring of ketoacidotic conditions. Ketoacidosis is a life threatening condition that needs immediate medical treatment, especially in diabetic patients.
Over the years, point of care testing (POCT) is also used in the making of beta-hydroxybutyrate testing and has underpinned a new avenue in the market. As sodium glucose cotransporter 2 (SGLT2) inhibitors are increasingly used in treating diabetes 2, euglycemic diabetic ketoacidosis has become a high safety concern for patients. Hence, beta-hydroxybutyrate testing is increasingly used in such diagnostic blind spots. Some of the key product types are meter sensor systems, kits, and test strips. Apart from the use of these tests in diabetic Ketoacidosis, they are also used in alcoholic ketoacidosis. Key end users are hospitals, clinics, diagnostic laboratories, and home care settings.
The study on the beta-hydroxybutyrate testing market offers a comprehensive insights and data-driven analysis of key clinical trends, epidemiology of the disease, share and size of top players, and new avenues.
Growing worldwide prevalence of diabetes and diabetes-related complications is a key factor boosting the beta-hydroxybutyrate testing market. Rising number of hyperglycemic patients has elevated the risk for diabetic ketoacidosis (DKA). Advances in quantification of ketone bodies in lab framework in developing economies have also boosted the expansion of the beta-hydroxybutyrate testing market.
A growing number of validation studies that have aimed at assessing the efficacy of quantitative βOHB assay has paved way to new avenues in the assays the beta-hydroxybutyrate testing market. A case in point is Ranbut βOHB assay on a recent Roche analyzer product. A growing number of players are leaning on unveiling technologies that offer more precise and reliable detection for ketosis. Several players are leaning on offering on-site POCT analysers.
In recent years, ketosis management for diabetics in pediatrics, especially in Type 1 diabetes, has attracted the attention of stakeholders in the beta-hydroxybutyrate testing market. Top players are also keen on improving the precision of assays by making substantial improvements in the methods used. Several players are constantly bring technological advancements by ramping up their investments in improving the detection rate of urinary and blood ketone detection. Some of them have also reduced the cost of commercial point-of-care β-hydroxybutyrate measurement devices, thereby increasing the accessibility, thus gaining a better foothold in the beta-hydroxybutyrate testing market. Most players have been keen on opening new diagnostic approach to hyperglycemic patients in a bid to stay ahead of others.
Some of the top players engaged in such strategies and gain shares in the beta-hydroxybutyrate testing market are BioAssay Systems, AAT Bioquest, Inc, Quest Diagnostics, Cayman Chemical, Randox Laboratories Ltd., Merck KGaA, Abcam plc, and EKF Diagnostics.
Some of the key regional segments in the beta-hydroxybutyrate testing market are North America, Europe, the Middle East, Latin America, and Middle East and Africa. Of these, North America has been increasing dynamic and attractive market for the past several years. Increasing incidence of diabetic ketoacidosis (DKA) and its complications in the region are bolstering the generation of opportunities in the regional market. A growing body of validation studies and constant technological advancements in the commercial assays are key to the growth avenues in the North America beta-hydroxybutyrate testing market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.